146 related articles for article (PubMed ID: 33062672)
21. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome.
Na JC; Nagaya N; Rha KH; Han WK; Kim IY
Clin Genitourin Cancer; 2019 Aug; 17(4):299-305.e1. PubMed ID: 31204211
[TBL] [Abstract][Full Text] [Related]
22. Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease.
Wu J; Wang H; Ricketts CJ; Yang Y; Merino MJ; Zhang H; Shi G; Gan H; Linehan WM; Zhu Y; Ye D
Cancer; 2019 Apr; 125(7):1060-1069. PubMed ID: 30548481
[TBL] [Abstract][Full Text] [Related]
23. Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing.
Wang J; Xi Z; Xi J; Zhang H; Li J; Xia Y; Yi Y
Cancer Cell Int; 2018; 18():159. PubMed ID: 30349421
[TBL] [Abstract][Full Text] [Related]
24. FOXC2 and CLIP4 : a potential biomarker for synchronous metastasis of ≤7-cm clear cell renal cell carcinomas.
Ahn J; Han KS; Heo JH; Bang D; Kang YH; Jin HA; Hong SJ; Lee JH; Ham WS
Oncotarget; 2016 Aug; 7(32):51423-51434. PubMed ID: 27283491
[TBL] [Abstract][Full Text] [Related]
25. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
26. Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis.
Mano R; Duzgol C; Ganat M; Goldman DA; Blum KA; Silagy AW; Walasek A; Sanchez A; DiNatale RG; Marcon J; Kashan M; Becerra MF; Benfante NE; Coleman JA; Kattan MW; Russo P; Akin O; Ostrovnaya I; Hakimi AA
Urol Oncol; 2021 Nov; 39(11):791.e17-791.e24. PubMed ID: 34580025
[TBL] [Abstract][Full Text] [Related]
27. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
[TBL] [Abstract][Full Text] [Related]
28. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract][Full Text] [Related]
29. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
[TBL] [Abstract][Full Text] [Related]
30. One-carbon metabolism pathway gene variants and risk of clear cell renal cell carcinoma in a Chinese population.
Zhang L; Meng X; Ju X; Cai H; Li P; Cao Q; Shao P; Qin C; Yin C
PLoS One; 2013; 8(11):e81129. PubMed ID: 24278388
[TBL] [Abstract][Full Text] [Related]
31. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
[TBL] [Abstract][Full Text] [Related]
32. Genomic profiles of renal cell carcinoma in a small Chinese cohort.
Tai S; Xu DD; Yu Z; Guan Y; Yin S; Xiao J; Xue S; Liang C
Front Oncol; 2023; 13():1095775. PubMed ID: 37427096
[TBL] [Abstract][Full Text] [Related]
33. Clear Cell Papillary Renal Cell Carcinoma Shares Distinct Molecular Characteristics and may be Significantly Associated With Higher Risk of Developing Second Primary Malignancy.
Tian X; Xu WH; Wu JL; Gan HL; Wang HK; Gu WJ; Qu YY; Zhang HL; Ye DW
Pathol Oncol Res; 2021; 27():1609809. PubMed ID: 34512202
[TBL] [Abstract][Full Text] [Related]
34. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
35. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
36. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
Ackroyd SA; Arguello D; Ramos P; Mahdi H; ElNaggar A; Winer I; Holloway R; Krivak T; Jones N; Turner VG; Herzog T; Chu C; Brown J; Mantia-Smaldone G
Gynecol Oncol; 2023 Feb; 169():164-171. PubMed ID: 36333181
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and Spectrum of Predisposition Genes With Germline Mutations Among Chinese Patients With Bowel Cancer.
Xie Z; Ke Y; Chen J; Li Z; Wang C; Chen Y; Ding H; Cheng L
Front Genet; 2021; 12():755629. PubMed ID: 35154239
[No Abstract] [Full Text] [Related]
38. Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma.
Tan X; Zhai Y; Chang W; Hou J; He S; Lin L; Yu Y; Xu D; Xiao J; Ma L; Wang G; Cao T; Cao G
Int J Cancer; 2008 Sep; 123(5):1080-8. PubMed ID: 18546293
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a metastasis-associated prognostic signature based on single-cell RNA-seq in clear cell renal cell carcinoma.
Zhang C; He H; Hu X; Liu A; Huang D; Xu Y; Chen L; Xu D
Aging (Albany NY); 2019 Nov; 11(22):10183-10202. PubMed ID: 31747386
[TBL] [Abstract][Full Text] [Related]
40. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
